Development of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy

Basit Öğe Kaydı
dc.contributor.authorEbik, Berat
dc.contributor.authorAygan, Mustafa
dc.contributor.authorTuncel, Elif Tugba
dc.contributor.authorKacmaz, Huseyin
dc.contributor.authorEkin, Nazim
dc.contributor.authorArpa, Medeni
dc.contributor.authorYalcin, Kendal
dc.date.accessioned2024-04-24T17:17:58Z
dc.date.available2024-04-24T17:17:58Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies. Materials and Methods: The medical data of patients who were diagnosed with HCV and received DAA therapy in two tertiary centers in Turkey were retrospectively collected. Results: Among them, 75 patients (52.4%) were noncirrhotic and 68 patients (47.6%) were cirrhotic. The overall SVR rate was 97.2% (139/143). It was 100% in noncirrhotic and 94.1% in cirrhotic patients. HCC was developed in 5 (7.4%) patients, all of whom had baseline cirrhosis. The annual rate of HCC occurrence was 2.94%, and the 5-year cumulative incidence of HCC was 7.3%. The mean Child-Pugh score (CPS) and Model for End-Stage Liver Disease (MELD) score significantly decreased after DAA treatment (CPS 7.0 vs 5.9, p=0.001; MELD 10.8 vs 9.5, =-0.003). Conclusion: There was no significant increase in the rate of HCC in cirrhotic HCV patients treated with DAAs. This treatment led to a remarkably high SVR rate and lowered CPS and MELD scores in cirrhotic HCV patients.en_US
dc.identifier.doi10.14744/hf.2022.2022.0016
dc.identifier.endpage87en_US
dc.identifier.issn1307-5888
dc.identifier.issn2757-7392
dc.identifier.issue3en_US
dc.identifier.pmid36177099
dc.identifier.startpage82en_US
dc.identifier.trdizinid1173909
dc.identifier.urihttps://doi.org/10.14744/hf.2022.2022.0016
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1173909
dc.identifier.urihttps://hdl.handle.net/11468/18491
dc.identifier.volume3en_US
dc.identifier.wosWOS:000863556400003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofHepatology Forum
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Hepatitis C Infectionen_US
dc.subjectDirect-Acting Antiviral Agentsen_US
dc.subjectHepatocellular Carcinomaen_US
dc.titleDevelopment of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapyen_US
dc.titleDevelopment of hepatocellular carcinoma in patients with chronic hepatitis C who had sustained viral response following direct-acting antiviral therapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu